Australia, June 18 -- Axsome Therapeutics Inc., owns the trademark (2519628) for 'AXSOME' and 'WORD THRU MOLECULAR-DIAGRAM' till July 19, 2034.
Status: protected:
Registered/protected
Classes: 5 [Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.], 9 [Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders.], 16 [Printed educational materials in the field of migraines.], 35 [Promoting public awareness of migraines.], 36 [Management of pharmacy benefit programs featuring a medical benefit co-pay card, namely, management of patient assistance eligibility programs featuring a pharmacy benefit co-pay card financial administration of patient assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for medical benefits.], 38 [Providing an on-line forum for patients and doctors to communicate and discuss depression and treatments for depression.] and 44 [Consulting services in the field of health relating to pharmaceuticals; providing health information relating to pharmaceuticals; providing health information relating to pharmaceuticals via a website; providing medical information relating to pharmaceuticals via a website; providing news and information in the field of medicine relating to pharmaceuticals; providing on-line information, news and commentary in the field of health and wellness relating to pharmaceuticals; providing health information; providing health information via a website; providing medical information via a website; providing medical information in the field of depression and treatments for depression; providing mental health information via a website; providing mental health and wellness information; providing news and information in the field of medicine; providing news and information in the field of mental health about depression and treatments for depression; providing on-line information, news and commentary in the field of health and wellness relating to depression and treatments for depression; providing information in the field of migraines, specifically, information relating to symptoms, prevalence, and treatment of migraines, and research data relating to migraines; Providing information in the field of migraines, specifically, information relating to symptoms, prevalence, and treatment of migraines, and data relating to migraines, via a website.]
Type of Mark: Figurative
Date of Acceptance: April 10
Registration Advertised: June 17
For further details contact Griffith Hack and Procopio, Cory, Hargreaves & Savitch LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2519628.
Disclaimer: Curated by HT Syndication.
